Carnation Therapeutics Inc

Carnation Therapeutics addresses some of the most pressing challenges in cancer treatment by unlocking targets that remain inaccessible to small molecules. Many oncogenic and immune-regulatory genes driving tumor growth and immune suppression have been considered “undruggable,” leaving patients with limited options. Our antisense oligonucleotide platform is designed for precision—using advanced AI/ML-guided sequence optimization to maximize potency while minimizing off-target effects. Through proprietary targeted delivery technologies, we ensure selective uptake into tumor and immune compartments, reducing systemic toxicity. By silencing key resistance pathways that undermine current immunotherapies, we aim to expand the number of patients who can respond and achieve durable benefit in oncology and immuno-oncology.